190 related articles for article (PubMed ID: 2668699)
1. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
[TBL] [Abstract][Full Text] [Related]
2. Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.
Serradas P; Bailbé D; Portha B
Diabetologia; 1989 Aug; 32(8):577-84. PubMed ID: 2528491
[TBL] [Abstract][Full Text] [Related]
3. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC
Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
[TBL] [Abstract][Full Text] [Related]
4. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
van der Wal PS; Heine RJ
Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus.
Wajchenberg BL; Santomauro AT; Giannella-Neto D; Borghi VC; Porrelli RN
Diabetes Res Clin Pract; 1992 Aug; 17(2):89-97. PubMed ID: 1425152
[TBL] [Abstract][Full Text] [Related]
7. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
Ligtenberg JJ; Reitsma WD; van Haeften TW
Horm Metab Res; 2001 Jun; 33(6):361-4. PubMed ID: 11456286
[TBL] [Abstract][Full Text] [Related]
8. Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.
Hosker JP; Burnett MA; Davies EG; Harris EA; Turner RC
Diabetologia; 1985 Nov; 28(11):809-14. PubMed ID: 3936738
[TBL] [Abstract][Full Text] [Related]
9. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
Diabet Med; 1991 Apr; 8(3):243-53. PubMed ID: 1828740
[TBL] [Abstract][Full Text] [Related]
10. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects.
Levy JC; Rudenski A; Burnett M; Knight R; Matthews DR; Turner RC
Diabetologia; 1991 Jul; 34(7):488-99. PubMed ID: 1916054
[TBL] [Abstract][Full Text] [Related]
11. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
Chazan AC; Gomes MB
Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
[TBL] [Abstract][Full Text] [Related]
12. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
Brogard JM; Pinget M; Dorner M
Curr Med Res Opin; 1984; 9(1):56-63. PubMed ID: 6373160
[TBL] [Abstract][Full Text] [Related]
13. Prednisolone enhances beta-cell function independently of ambient glycemic levels in type II diabetes.
Hosker JP; Burnett MA; Matthews DR; Turner RC
Metabolism; 1993 Sep; 42(9):1116-20. PubMed ID: 8412763
[TBL] [Abstract][Full Text] [Related]
14. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
15. The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
Matthews DR; Boland O
Metabolism; 1997 Dec; 46(12 Suppl 1):5-9. PubMed ID: 9439551
[TBL] [Abstract][Full Text] [Related]
16. The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
Karunakaran S; Hammersley MS; Morris RJ; Turner RC; Holman RR
Metabolism; 1997 Dec; 46(12 Suppl 1):56-60. PubMed ID: 9439561
[TBL] [Abstract][Full Text] [Related]
17. Effect of prolonged gliclazide therapy in non-insulin dependent diabetic subjects.
Donatelli M; Sinagra D; Russo V; Bucalo ML; Giardina E; Cerasola GA; Bompiani G
Pharmatherapeutica; 1985; 4(2):69-75. PubMed ID: 3903780
[TBL] [Abstract][Full Text] [Related]
18. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
[TBL] [Abstract][Full Text] [Related]
19. Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
Della Casa L; del Rio G; Glaser B; Cerasi E
Diabetes Res Clin Pract; 1991; 14 Suppl 2():S69-78. PubMed ID: 1794269
[TBL] [Abstract][Full Text] [Related]
20. Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
Kawai K; Suzuki S; Murayama Y; Watanabe Y; Yamashita K
Diabetes Res Clin Pract; 1991 Jul; 12(3):163-72. PubMed ID: 1832376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
